These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15105159)

  • 1. In vitro activity of anidulafungin against selected clinically important mold isolates.
    Odabasi Z; Paetznick VL; Rodriguez JR; Chen E; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2004 May; 48(5):1912-5. PubMed ID: 15105159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM; Szekely A; Warnock DW
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
    Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
    Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
    Najafzadeh MJ; Badali H; Illnait-Zaragozi MT; De Hoog GS; Meis JF
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1636-8. PubMed ID: 20086140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
    Gilgado F; Serena C; Cano J; Gené J; Guarro J
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
    González GM; Fothergill AW; Sutton DA; Rinaldi MG; Loebenberg D
    Med Mycol; 2005 May; 43(3):281-4. PubMed ID: 16010855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
    Radford SA; Johnson EM; Warnock DW
    Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
    Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
    J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
    Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
    J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
    Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
    J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of voriconazole against selected fungi.
    McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
    Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
    González GM
    Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.
    Johnson EM; Szekely A; Warnock DW
    Antimicrob Agents Chemother; 1999 May; 43(5):1260-3. PubMed ID: 10223947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.